Abstract:Valbenazine and deutetrabenazine are the only two therapeutic drugs approved for tardive dyskinesia based on blocking the action of vesicular monoamine transporter 2 (VMAT2). But there exist demethylated inactive metabolism at the nine position for both them resulting in low availability, and CYP2D6 plays a major role in this metabolism resulting in the genetic polymorphism issue. 9-trifluoroethoxy-dihydrotetrabenazine (13e) was identified as a promising lead compound for treating tardive dyskinesia. In this study, we separated 13e via chiral chromatography and acquired R,R,R-13e [(+)-13e] and S,S,S-13e [(−)-13e], and we investigated their VMAT2-inhibitory activity and examined the related pharmacodynamics and pharmacokinetics properties using in vitro and in vivo models (+)-13e displayed high affinity for VMAT2 (Ki = 1.48 nM) and strongly inhibited [3H]DA uptake (IC50 = 6.11 nM) in striatal synaptosomes. Conversely, its enantiomer was inactive. In vivo, (+)-13e decreased locomotion in rats in a dose-dependent manner. The treatment had faster, stronger, and longer-lasting effects than valbenazine at an equivalent dose. Mono-oxidation was the main metabolic pathway in the liver microsomes and in dog plasma after oral administration, and glucuronide conjugation of mono-oxidized and/or demethylated products and direct glucuronide conjugation were also major metabolic pathways in dog plasma. O-detrifluoroethylation of (+)-13e did not occur. Furthermore, CYP3A4 was identified as the primary isoenzyme responsible for mono-oxidation and demethylation metabolism, and CYP2C8 was a secondary isoenzyme (+)-13e displayed high permeability across the Caco-2 cell monolayer, and it was not a P-glycoprotein substrate as demonstrated by its high oral absolute bioavailability (75.9%) in dogs. Thus, our study findings highlighted the potential efficacy and safety of (+)-13e in the treatment of tardive dyskinesia. These results should promote its clinical development.

Drug inhibition and substrate alternating flipping mechanisms of human VMAT2

Transport and inhibition mechanisms of human VMAT2

Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines

Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2

Structural mechanisms for VMAT2 inhibition by tetrabenazine

Structural snapshots of human VMAT2 reveal insights into substrate recognition and proton coupling mechanism

Neurotransmitter recognition by human vesicular monoamine transporter 2

Structure-Based Specific Detection And Inhibition Of Monoamine Oxidases And Their Applications In Central Nervous System Diseases

9-Cyclopropylmethoxy-dihydrotetrabenazine and Its Stereoisomers As Vesicular Monoamine Transporter-2 Inhibitors

VMAT structures reveal exciting targets for drug development

Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variants

Retrograde Trafficking of VMAT2 and Its Role in Protein Stability in Non-Neuronal Cells

Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters.

Preparation and Evaluation of Tetrabenazine Enantiomers and All Eight Stereoisomers of Dihydrotetrabenazine As VMAT2 Inhibitors.

Vesicular neurotransmitter transporter trafficking in vivo

(+)-9-Trifluoroethoxy-α-dihydrotetrabenazine As a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia

Dopamine reuptake and inhibitory mechanisms in human dopamine transporter

Tetrabenazine, a vesicular monoamine transporter 2 inhibitor, inhibits vesicular storage capacity and release of monoamine transmitters in mouse brain tissue

Substrate-induced Conformational Dynamics of the Dopamine Transporter

Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis